共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
Qiu Rao Qiu-Yuan Xia Qin Shen Shan-Shan Shi Pin Tu Qun-Li Shi Xiao-Jun Zhou 《International journal of clinical and experimental pathology》2014,7(4):1782-1787
In this study, we analyzed the immunohistochemical and molecular profiles of an unusual RCC showed coexistent absence of INI1 and BRG1 expression, rhabdoid morphology, and poor prognosis. Histologically, the tumor had rhabdoid features, which were demonstrated by large round to polygonal cells with eccentric nuclei, prominent nucleoli, and eosinophilic cytoplasm varying from abundant to scanty. Immunohistochemically, the tumor were positive for BRM, PBRM1, ARID1A, CD10, CKpan, Vimentin, carbonic anhydrase IX (CA-IX), and P504S (AMACR) but negative for INI1, BRG1, HMB45, melan A, CK7, CD117, Ksp-cadherin, TFEB, TFE3, and Cathepsin K. We detected all three exons status of the VHL gene of the tumor and observed 1 somatic mutations in 1st exon. Chromosome 3p deletion, coupled with polysomy of chromosome 3 was also found. Based on these findings, it is further indicated that in some cases, rhabdoid RCC may arise from clear cell RCC. SWI/SNF chromatin remodeling complex may be an attractive candidate for being the “second hit” in RCCs and may play an important role during tumor progression. The role of SWI/SNF complex in rhabdoid RCC should be further studied on a larger number of cases. 相似文献
3.
Y. Tsurusaki N. Okamoto H. Ohashi S. Mizuno N. Matsumoto Y. Makita M. Fukuda B. Isidor J. Perrier S. Aggarwal A.B. Dalal A. Al‐Kindy J. Liebelt D. Mowat M. Nakashima H. Saitsu N. Miyake N. Matsumoto 《Clinical genetics》2014,85(6):548-554
Coffin–Siris syndrome (CSS) is a congenital disorder characterized by intellectual disability, growth deficiency, microcephaly, coarse facial features, and hypoplastic or absent fifth fingernails and/or toenails. We previously reported that five genes are mutated in CSS, all of which encode subunits of the switch/sucrose non‐fermenting (SWI/SNF) ATP‐dependent chromatin‐remodeling complex: SMARCB1, SMARCA4, SMARCE1, ARID1A, and ARID1B. In this study, we examined 49 newly recruited CSS‐suspected patients, and re‐examined three patients who did not show any mutations (using high‐resolution melting analysis) in the previous study, by whole‐exome sequencing or targeted resequencing. We found that SMARCB1, SMARCA4, or ARID1B were mutated in 20 patients. By examining available parental samples, we ascertained that 17 occurred de novo. All mutations in SMARCB1 and SMARCA4 were non‐truncating (missense or in‐frame deletion) whereas those in ARID1B were all truncating (nonsense or frameshift deletion/insertion) in this study as in our previous study. Our data further support that CSS is a SWI/SNF complex disorder. 相似文献
4.
Frequent co‐inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Qiu Rao Qiu‐yuan Xia Zi‐yu Wang Li Li Qin Shen Shan‐shan Shi Xuan Wang Biao Liu Yan‐fen Wang Qun‐li Shi Heng‐hui Ma Zhen‐feng Lu Yan He Ru‐song Zhang Bo Yu Xiao‐jun Zhou 《Histopathology》2015,67(1):121-129
5.
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary,hypercalcaemic type
下载免费PDF全文
![点击此处可从《The Journal of pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
William PD Hendricks Esther Oliva Emanuela D'Angelo Jaime Prat Marisa R Nucci Torsten O Nielsen Christine Chow Samuel Leung Friedrich Kommoss Stefan Kommoss Annacarolina Silva Brigitte M Ronnett Joseph T Rabban David D Bowtell Bernard E Weissman Jeffrey M Trent C Blake Gilks David G Huntsman 《The Journal of pathology》2016,238(3):389-400
Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a lethal and sometimes familial ovarian tumour of young women and children. We and others recently discovered that over 90% of SCCOHTs harbour inactivating mutations in the chromatin remodelling gene SMARCA4 with concomitant loss of its encoded protein SMARCA4 (BRG1), one of two mutually exclusive ATPases of the SWI/SNF chromatin remodelling complex. To determine the specificity of SMARCA4 loss for SCCOHT, we examined the expression of SMARCA4 by immunohistochemistry in more than 3000 primary gynaecological tumours. Among ovarian tumours, it was only absent in clear cell carcinoma (15 of 360, 4%). In the uterus, it was absent in endometrial stromal sarcomas (4 of 52, 8%) and high‐grade endometrioid carcinomas (2 of 338, 1%). Recent studies have shown that SMARCA2 (BRM), the other mutually exclusive ATPase of the SWI/SNF complex, is necessary for survival of tumour cells lacking SMARCA4. Therefore, we examined SMARCA2 expression and discovered that all SMARCA4‐negative SCCOHTs also lacked SMARCA2 protein by IHC, including the SCCOHT cell lines BIN67 and SCCOHT1. Among ovarian tumours, the SMARCA4/SMARCA2 dual loss phenotype appears completely specific for SCCOHT. SMARCA2 loss was not due to mutation but rather from an absence of mRNA expression, which was restored by treatment with the histone deacetylase inhibitor trichostatin A. Re‐expression of SMARCA4 or SMARCA2 inhibited the growth of BIN67 and SCCOHT1 cell lines. Our results indicate that SMARCA4 loss, either alone or with SMARCA2, is highly sensitive and specific for SCCOHT and that restoration of either SWI/SNF ATPase can inhibit the growth of SCCOHT cell lines. © 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. 相似文献
6.
Tomoki Kosho Nobuhiko Okamoto Hirofumi Ohashi Yoshinori Tsurusaki Yoko Imai Yumiko Hibi‐Ko Hiroshi Kawame Tomomi Homma Saori Tanabe Mitsuhiro Kato Yoko Hiraki Takanori Yamagata Shoji Yano Satoru Sakazume Takuma Ishii Toshiro Nagai Tohru Ohta Norio Niikawa Seiji Mizuno Tadashi Kaname Kenji Naritomi Yoko Narumi Keiko Wakui Yoshimitsu Fukushima Satoko Miyatake Takeshi Mizuguchi Hirotomo Saitsu Noriko Miyake Naomichi Matsumoto 《American journal of medical genetics. Part A》2013,161(6):1221-1237
7.
Prabodh Kapoor Yunhe Bao Jing Xiao Jie Luo Jianfeng Shen Jim Persinger Guang Peng Jeff Ranish Blaine Bartholomew Xuetong Shen 《Genes & development》2015,29(6):591-602
ATP-dependent chromatin remodeling complexes alter chromatin structure through interactions with chromatin substrates such as DNA, histones, and nucleosomes. However, whether chromatin remodeling complexes have the ability to regulate nonchromatin substrates remains unclear. Saccharomyces cerevisiae checkpoint kinase Mec1 (ATR in mammals) is an essential master regulator of genomic integrity. Here we found that the SWI/SNF chromatin remodeling complex is capable of regulating Mec1 kinase activity. In vivo, Mec1 activity is reduced by the deletion of Snf2, the core ATPase subunit of the SWI/SNF complex. SWI/SNF interacts with Mec1, and cross-linking studies revealed that the Snf2 ATPase is the main interaction partner for Mec1. In vitro, SWI/SNF can activate Mec1 kinase activity in the absence of chromatin or known activators such as Dpb11. The subunit requirement of SWI/SNF-mediated Mec1 regulation differs from that of SWI/SNF-mediated chromatin remodeling. Functionally, SWI/SNF-mediated Mec1 regulation specifically occurs in S phase of the cell cycle. Together, these findings identify a novel regulator of Mec1 kinase activity and suggest that ATP-dependent chromatin remodeling complexes can regulate nonchromatin substrates such as a checkpoint kinase. 相似文献
8.
Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung
下载免费PDF全文
![点击此处可从《Pathology international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Taichiro Yoshimoto Daisuke Matsubara Tomoyuki Nakano Tomoko Tamura Shunsuke Endo Yukihiko Sugiyama Toshiro Niki 《Pathology international》2015,65(11):595-602
The switch/sucrose non‐fermenting (SWI/SNF) complex has recently emerged as a novel tumor suppressor in various human cancers. In the present study, we analyzed the expression of multiple SWI/SNF subunits in primary non‐small cell lung cancer (NSCLC). A total of 133 NSCLC, consisting of 25 squamous cell carcinomas (SCC), 70 adenocarcinomas (AD), 16 large cell carcinomas (LC), and 22 pleomorphic carcinomas (PL), were immunohistochemically examined for the expression of BRG1, BRM, BAF47, ARID1A, and ARID1B. The frequency at which reductions in the expression of BRG1 were observed was significantly higher in the LC‐PL group (13/38, 34.2%) than in the SCC‐AD group (7/95, 7.4%). Similarly, the frequency at which reductions in the expression of BRM were observed was significantly higher in the LC‐PL group (17/38, 44.7%) than in the SCC‐AD group (14/95, 14.7%). The loss of the expression of ARID1A, ARID1B, and BAF47 was observed only in a fraction of NSCLC cases. Furthermore, the frequency at which the concurrent loss of multiple subunits of the SWI/SNF complex was observed was significantly higher in the LC‐PL group (10/38, 26.3%) than in the SCC‐AD group (8/95, 8.4%). Collectively, these results indicate that the loss of the SWI/SNF complex was related to dedifferentiation in NSCLC. 相似文献
9.
10.
Junwei Shi Warren A. Whyte Cinthya J. Zepeda-Mendoza Joseph P. Milazzo Chen Shen Jae-Seok Roe Jessica L. Minder Fatih Mercan Eric Wang Melanie A. Eckersley-Maslin Amy E. Campbell Shinpei Kawaoka Sarah Shareef Zhu Zhu Jude Kendall Matthias Muhar Christian Haslinger Ming Yu Robert G. Roeder Michael H. Wigler Gerd A. Blobel Johannes Zuber David L. Spector Richard A. Young Christopher R. Vakoc 《Genes & development》2013,27(24):2648-2662
11.
BRM/SMARCA2‐negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations,deletions and promoter methylation
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Qiu‐Yuan Xia Xue‐Mei Zhan Xiang‐Shan Fan Sheng‐Bing Ye Shan‐Shan Shi Rui Li Xue Wei Xuan Wang Heng‐Hui Ma Zhen‐Feng Lu Xiao‐Jun Zhou Qiu Rao 《Histopathology》2017,70(5):711-721
12.
Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small‐cell carcinoma of the ovary,hypercalcaemic type distinguishes these tumours from their mimics
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Blaise A Clarke Leora Witkowski Tuyet N Ton Nu Patricia A Shaw C Blake Gilks David Huntsman Anthony N Karnezis Neil Sebire Janez Lamovec Lawrence M Roth Colin J R Stewart Martin Hasselblatt William D Foulkes W Glenn McCluggage 《Histopathology》2016,69(5):727-738
13.
William D Foulkes Blaise A Clarke Martin Hasselblatt Jacek Majewski Steffen Albrecht W Glenn McCluggage 《The Journal of pathology》2014,233(3):209-214
Whole‐exome sequencing (WES) is revolutionizing medical diagnostics and taxonomy. In less than 5 years since its first use, WES has revealed unexpected molecular drivers of numerous cancers. Here, we describe our use of WES to uncover the true nature of an enigmatic pathological entity, small‐cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), which has resisted definitive characterisation since it was first described in 1979. We conducted WES using three families with SCCOHT and identified deleterious mutations in the chromatin‐remodelling gene SMARCA4 (encoding BRG1) in all cases. Follow‐up of these findings, using both Sanger sequencing and WES of formalin‐fixed paraffin‐embedded tumours, showed that virtually all SCCOHTs we studied lacked functional SMARCA4/BRG1. Notably, this gene, and the related SMARCB1 gene, is mutated in most, if not all, atypical teratoid/rhabdoid tumours and malignant rhabdoid tumours. Other groups have similar findings. We review the relationship between these three neoplasms, discuss how they were distinguished from morphologically similar neoplasms, consider their similarities and show how WES has revealed that SCCOHTs are in fact rhabdoid tumours. We propose that SCCOHT be renamed ‘malignant rhabdoid tumour of the ovary’ (MRTO) to reflect these observations. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献
14.
Hiroko Fukushima Kai Yamasaki Miho Sakaida Nozomi Tsujio Takahiro Okuno Naomi Ishii Keiko Okada Hiroyuki Fujisaki Yasuhiro Matsusaka Hiroaki Sakamoto Akihiro Yoneda Junichi Hara Takeshi Inoue 《Pathology international》2021,71(2):155-160
We report a case of rhabdoid tumor predisposition syndrome with a renal tumor developing 10 years after a brain tumor, which demonstrated an unexpectedly favorable outcome. A 2-year-old boy underwent gross total resection of a brain tumor located in the fourth ventricle, and received adjuvant chemotherapy and radiotherapy. At the age of 11 years, a renal tumor was found and nephrectomy was performed. He is currently alive without evidence of disease over 2 years without postoperative therapy. Histologically, rhabdoid cells were observed in both brain and renal tumors. Loss of SMARCB1 (also known as INI1) expression was found in the nucleus of both tumor cells. Genetic testing revealed pathogenic variants of SMARCB1 exon 5 in the renal tumor and SMARCB1 exon 9 in the brain tumor. In addition, heterozygous deletion of 22q11.21-q11.23 containing the SMARCB1 locus was shared by both tumors and this deletion was identified in normal peripheral blood. Considering the histopathological and genetic findings, our case was considered to be rhabdoid tumor predisposition syndrome with atypical teratoid/rhabdoid tumor and late-onset rhabdoid tumor of the kidney. 相似文献
15.
16.
17.
SMARCA4 inactivating mutations cause concomitant Coffin–Siris syndrome,microphthalmia and small‐cell carcinoma of the ovary hypercalcaemic type
下载免费PDF全文
![点击此处可从《The Journal of pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Edoardo Errichiello Noor Mustafa Annalisa Vetro Lucia Dora Notarangelo Hugo de Jonge Berardo Rinaldi Debora Vergani Sabrina Rita Giglio Patrizia Morbini Orsetta Zuffardi 《The Journal of pathology》2017,243(1):9-15
18.
Misawa A Hosoi H Imoto I Iehara T Sugimoto T Inazawa J 《Journal of human genetics》2004,49(10):586-589
Malignant rhabdoid tumor (MRT) is a highly malignant pediatric cancer, which arises in various sites such as the kidney, brain, and soft tissues. Cytogenetic studies have revealed alterations of 22q11 in MRT. Recently, deletions and mutations of the SNF5/INI1 locus in 22q11.2 have been reported in MRT, suggesting that SNF5/INI1 is a tumor suppressor gene for MRT. Here we report our molecular cytogenetic study for a newly established cell line from extrarenal MRT with t(1;22)(p36;q11.2). Consequently, the reciprocal translocation was associated with the interstitial deletion of a small segment including SNF5/INI1, and another, chromosome 22, showed terminal deletion, the breakpoint of which was located 70–80 kb centromeric to SNF5/INI1, resulting in homozygous deletion of SNF5/INI1 in this cell line. 相似文献
19.
《Seminars in diagnostic pathology》2018,35(3):161-169
The identification of at-risk kindreds facilitates screening and risk reduction strategies for patients with hereditary cancer predisposition syndromes. Recently, immunohistochemistry (IHC) has emerged as a cost-effective strategy for detecting or inferring the presence of mutations in both tumors and the germline of patients presenting with tumors associated with hereditary cancer predisposition syndromes. In this review we discuss the use of novel IHC markers, including PRKAR1A, β-catenin, SDHB, fumarate hydratase and 2SC, HRASQ61R, BAP1, parafibromin and glucagon, which have either established applications or show promise for surgical pathologists to complement morphological or clinical suspicion of hereditary cancer predisposition syndromes. Specifically, we focus on Carney complex, familial adenomatous polyposis (FAP)-associated cribriform-morular variant of papillary thyroid carcinoma, familial succinate dehydrogenase-related pheochromocytoma/paraganglioma syndromes, hereditary leiomyomatosis and renal cell cancer (HLRCC), medullary thyroid cancer and Multiple Endocrine Neoplasia 2 (MEN2), BAP1 hereditary cancer predisposition syndrome, Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT), and Pancreatic Neuroendocrine Tumor Syndrome (Mahvash disease). 相似文献
20.
Kersemaekers AM Honecker F Stoop H Cools M Molier M Wolffenbuttel K Bokemeyer C Li Y Lau YF Oosterhuis JW Looijenga LH 《Human pathology》2005,36(5):512-521
Carcinoma in situ (CIS) is the precursor of malignant testicular germ cell tumors (GCTs) of adolescents and young adults, being the neoplastic counterpart of primordial germ cells/gonocytes. Carcinoma in situ cells will develop into invasive seminoma/nonseminoma. Gonadoblastoma (GB) is the precursor of invasive GCTs in dysgenetic gonads, predominantly dysgerminoma (DG). In this process, part of the Y chromosome (GBY region) is involved, for which TSPY is a candidate gene. A detailed immunohistochemical survey was performed for the known diagnostic markers, germ cell/placental alkaline phosphatase (PLAP), c-KIT, and OCT3/4, as well as testis-specific protein on the Y chromosome (TSPY) on a series of GBs, and adjacent invasive DGs. All 5 patients were XY individuals (4 females and 1 male). In contrast to c-KIT, PLAP was positive in all cases. The immature germ cells of GBs were positive for OCT3/4, whereas the mature germ cells were negative for this marker, but positive for TSPY. In every GB, a minor population of germ cells positive for both markers could be identified, similar to most CIS cells and early invasive DG. On progression to an invasive tumor, TSPY can be lost, a process that is also detectable in invasive testicular GCTs compared to CIS. These results indicate that GB is a heterogeneous mix of germ cells, in which the OCT3/4-positive cells have the potential to undergo progression to an invasive tumor. These early invasive stages are initially also positive for TSPY (like CIS), supporting a positive selection mechanism. Therefore, OCT3/4 in combination with TSPY is valuable to identify malignant germ cells in dysgenetic gonads. This could allow better prediction of the risk of progression to a GCT. In addition, the data support the model that GB represents the earliest accessible developmental stage of malignant GCTs. 相似文献